The UCSF spinout aims to develop noninvasive tests to detect kidney injury for the transplantation field and to diagnose and monitor chronic disease.
The trials are part of the second phase of the Implementing Genomics in Practice program, which is slated to receive $42 million in funding over 5 years.
A LIMS1 gene variant appeared to coincide with increased risk of allograft rejection in kidney transplant recipients.
The company's new KidneyCare test will include AlloSure for rejection, AlloMap for quiescence, and Cibiltech's AI algorithm for graft health information.
Investigators identified a set of inflammatory proteins that appears to coincide with current and future risk of end-stage renal disease in individuals with diabetes.
The company said its testing services revenues for the quarter rose nearly 120 percent year over year.
The companies will develop an IVD system based on the MiniSeq initially to diagnose hereditary kidney disease.
The company is currently conducting clinical studies to validate AlloSure's technology — which underlies its kidney transplant test — in lung transplant patients.
The investment bank said the company is strongly positioned as a leader in the transplant diagnostics market with tests that serve an unmet need.
A new analysis found kidney disease-related pathogenic or likely pathogenic variants in exomes for roughly 9 percent of individuals with chronic kidney disease.
A new analysis finds that nearly half the late-stage clinical trials sponsored by a US National Cancer Institute program influence patient care.
Technology Review reports that sickle cell patients are optimistic about gene editing to treat their disease, but are worried about how available it will be.
The owner of the GEDmatch website tells CBS12 he is considering charging law enforcement a fee to use the site.
In Nature this week: babies born by caesarean section are more likely to have altered gut microbiota profiles, and more.